Grant: Alliance Grants
University of Toronto
$70,000.00
Validating multi-modal therapeutic targets of bio-inorganic drug compounds benefiting skin diseases
EF 2024-25
Résumé
Background and motivation: Atopic Dermatitis (AD), the most common form of eczema is a long-lasting skin disease caused by an ineffective skin barrier leading to dryness, irritation and inflammation. It affects up to 20% of Canadians at some point of their life, associated with an estimated >$1.4B annually. Current treatments with steroids offer symptom relief only, and harsh side effects preclude long-term use. Thus, there is an urgent need for new treatment options to address skin dysfunction and provide long-term disease control. Noa Therapeutics Inc. (Noa) developed a series of new agents referred to as trimodal therapeutic compounds (TMTs), due to their three effects: 1) pro-healing effects that accelerate repair of skin cell barrier functions; 2) induction of anti-inflammatory mediators; and 3) broad-spectrum antimicrobial efficacy. These effects can promote healing and address infection, which often complicates therapy. However, there are significant knowledge gaps of mechanisms of action of these agents.
Team: Noa, a Canadian biotechnology company leads discovery of non-steroidal small molecules for skin disease therapy. Academic partners Dr Bohle (McGill University) and Dr Szaszi (University of Toronto) have decades of experience studying compounds affecting cell functions and cellular mechanisms.
Objective and aims: To obtaining an understanding of the relationship between molecular structure and cellular mechanisms of action of Noa's TMTs. Aim 1 (Dr Bohle, McGill University) will characterize structure, stability, and biological interactions of the TMTs in-vitro. Aim 2 and 3 (Dr Szaszi, University of Toronto) will investigate effects and mechanism of action using cultured skin cells and complex skin models.
Project outcome and significance: This strategic alliance will address a significant unmet need for more efficacious and safter treatment options in AD. The new knowledge is crucial for developing therapeutic formulation and moving the drug candidates towards clinical trials.
Programme
Alliance Grants
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
NSERC's Awards Data
Tel que publié
Application id
590375-2023
Name nom
Szaszi, Katalin K
Department département
Surgery
Organization id
31
Institution établissement
University of Toronto
Province en
Ontario
Province fr
Ontario
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2024
Competition year année de concours
2023
Award amount
70000
Program id
ALLRP
Program name en
Alliance Grants
Program name fr
Subventions Alliance
Group en
RESEARCH PARTNERSHIPS
Group fr
PARTENARIATS DE RECHERCHE
Committee code
96
Committee name en
RPP Internal Decision Cttee
Committee name fr
Cté de décision interne - PPR
Area of application code
504
Area of application group en
Manufacturing processes and products
Area of application group fr
Procédés et produits industriels
Area of application en
Human pharmaceuticals
Area of application fr
Produits pharmaceutiques administrables à l'homme
Research subject code
5100
Research subject group en
Cell biology
Research subject group fr
Biologie cellulaire
Research subject en
Cell biology
Research subject fr
Biologie cellulaire
Field of research list names en
Not available
Field of research list names fr
Non disponible
Socioeconomic objective list names en
Not available
Socioeconomic objective list names fr
Non disponible
Application title
Validating multi-modal therapeutic targets of bio-inorganic drug compounds benefiting skin diseases
Keywords
anti-bacterial agent; cell signalling; drug effects; inflammation; keratinocytes; skin; tri-modal agents
Application summary
Background and motivation: Atopic Dermatitis (AD), the most common form of eczema is a long-lasting skin disease caused by an ineffective skin barrier leading to dryness, irritation and inflammation. It affects up to 20% of Canadians at some point of their life, associated with an estimated >$1.4B annually. Current treatments with steroids offer symptom relief only, and harsh side effects preclude long-term use. Thus, there is an urgent need for new treatment options to address skin dysfunction and provide long-term disease control. Noa Therapeutics Inc. (Noa) developed a series of new agents referred to as trimodal therapeutic compounds (TMTs), due to their three effects: 1) pro-healing effects that accelerate repair of skin cell barrier functions; 2) induction of anti-inflammatory mediators; and 3) broad-spectrum antimicrobial efficacy. These effects can promote healing and address infection, which often complicates therapy. However, there are significant knowledge gaps of mechanisms of action of these agents.
Team: Noa, a Canadian biotechnology company leads discovery of non-steroidal small molecules for skin disease therapy. Academic partners Dr Bohle (McGill University) and Dr Szaszi (University of Toronto) have decades of experience studying compounds affecting cell functions and cellular mechanisms.
Objective and aims: To obtaining an understanding of the relationship between molecular structure and cellular mechanisms of action of Noa's TMTs. Aim 1 (Dr Bohle, McGill University) will characterize structure, stability, and biological interactions of the TMTs in-vitro. Aim 2 and 3 (Dr Szaszi, University of Toronto) will investigate effects and mechanism of action using cultured skin cells and complex skin models.
Project outcome and significance: This strategic alliance will address a significant unmet need for more efficacious and safter treatment options in AD. The new knowledge is crucial for developing therapeutic formulation and moving the drug candidates towards clinical trials.